Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has filed a request for regulatory clearance to begin a Phase 1/2a clinical trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE